SCHEMBL16669014

SCHEMBL16669014

Clc1cc(-c2ccccc2)nc2c1CCC2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HPGD P15428 3/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ACHE P22303 7/20 0.47
BCHE P06276 4/20 0.45
KDM4E B2RXH2 5/20 0.44
ADORA2A P29274 1/20 0.44
PDE4B Q07343 3/20 0.42
GRIN1 Q05586 2/20 0.42
GRIN2A Q12879 2/20 0.42
ADORA1 P30542 1/20 0.42
HSD17B10 Q99714 3/20 0.42
MAPT P10636 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2D6 P10635 2/20 0.42
TSHR P16473 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2624107 0.97 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL15947858 0.87 KDM4E (0.45) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
SCHEMBL15659086 0.86 PDE4B (0.55) ALDH1A1SMN1; SMN2HPGDACHEBCHE
Hydrochloric Acid SCHEMBL29710392 0.84 PDE4B (0.54) ALDH1A1SMN1; SMN2HPGDACHEBCHE
Hydrochloric Acid SCHEMBL15660495 0.84 PDE4B (0.54) ALDH1A1SMN1; SMN2HPGDACHEBCHE
SCHEMBL16682856 0.83 MAPT (0.45) ALDH1A1SMN1; SMN2HPGDMEN1KMT2A
Hydrochloric Acid SCHEMBL16669168 0.82 MAPT (0.44) ALDH1A1SMN1; SMN2HPGDKMT2AL3MBTL1
SCHEMBL15948068 0.82 HPGD (0.51) ALDH1A1HPGDACHEBCHEPDE4B
SCHEMBL15948076 0.81 ACHE (0.45) ALDH1A1SMN1; SMN2HPGDL3MBTL1ACHE
SCHEMBL23975793 0.80 TDP1 (0.41) ALDH1A1SMN1; SMN2ACHEBCHEKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 US disclosed
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-01-26 US disclosed
EP-3842420-B1 HETEROARYL INHIBITORS OF PDE4 TETRA DISCOVERY PARTNERS LLC (US) 2022-12-07 EP disclosed
US-11401286-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2022-08-02 US disclosed
EP-3842420-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners LLC (US) 2021-06-30 EP disclosed
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2020-11-12 US disclosed
US-10626129-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2020-04-21 US disclosed
US-20190270759-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2019-09-05 US disclosed
US-10364258-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2019-07-30 US disclosed
US-20190055269-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2019-02-21 US disclosed
US-10093686-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2018-10-09 US disclosed
US-20170342094-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2017-11-30 US disclosed
US-9777024-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2017-10-03 US disclosed
US-20160137672-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2016-05-19 US disclosed
US-9221843-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2015-12-29 US disclosed
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2015-04-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190270759-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20200354384-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20230024240-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20150119362-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 751/4885SMN1; SMN2 3143/4885HPGD 222/4885
US-11401286-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20190055269-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20170342094-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-10093686-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-10626129-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-10364258-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 1152/4885SMN1; SMN2 4209/4885HPGD 140/4885
US-20160137672-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C ALDH1A1 751/4885SMN1; SMN2 3143/4885HPGD 222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.